Types of Research
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove Poverty filter Poverty
Studies of improved seed adoption in developing countries almost always draw from household surveys and are premised on the assumption that farmers are able to self-report their use of improved seed varieties. However, recent studies suggest that farmers’ reports of the seed varieties planted, or even whether seed is local or improved, are sometimes inconsistent with the results of DNA fingerprinting of farmers' crops. We use household survey data from Tanzania to test the alignment between farmer-reported and DNA-identified maize seed types planted in fields. In the sample, 70% of maize seed observations are correctly reported as local or improved, while 16% are type I errors (falsely reported as improved) and 14% are type II errors (falsely reported as local). Type I errors are more likely to have been sourced from other farmers, rather than formal channels. An analysis of input use, including seed, fertilizer, and labor allocations, reveals that farmers tend to treat improved maize differently, depending on whether they correctly perceive it as improved. This suggests that errors in farmers' seed type awareness may translate into suboptimal management practices. In econometric analysis, the measured yield benefit of improved seed use is smaller in magnitude with a DNA-derived categorization, as compared with farmer reports. The greatest yield benefit is with correctly identified improved seed. This indicates that investments in farmers' access to information, seed labeling, and seed system oversight are needed to complement investments in seed variety development.
Self-Help Groups (SHGs) in Sub-Saharan Africa can be defined as mutual assistance organizations through which individuals undertake collective action in order to improve their own lives. “Collective action” implies that individuals share their time, labor, money, or other assets with the group. In a recent EPAR data analysis, we use three nationally-representative survey tools to examine various indicators related to the coverage and prevalence of Self-Help Group usage across six Sub-Saharan African countries. EPAR has developed Stata .do files for the construction of a set of self-help group indicators using data from the Living Standards Measurement Study - Integrated Surveys on Agriculture (LSMS-ISA), Financial Inclusion Index (FII), and FinScope.
We compiled a set of summary statistics for the final indicators using data from the following survey instruments:
- Ethiopia Socioeconomic Survey (ESS), Wave 3 (2015-16)
- Kenya FinScope, Wave 4 (2015)
- Kenya FII, Wave 4 (2016)
- Nigeria FII, Wave 4 (2016)
- Rwanda FII, Wave 4 (2016)
- Tanzania National Panel Survey (TNPS), Wave 4 (2014-15)
- Tanzania FinScope, Wave 4 (2017)
- Tanzania FII, Wave 4 (2016)
- Uganda FinScope, Wave 3 (2013)
- Uganda FII, Wave 4 (2016)
The raw survey data files are available for download free of charge from the World Bank LSMS-ISA website, the Financial Sector Deepening Trust website, and the Financial Inclusion Insights website. The .do files process the data and create final data sets at the household (LSMS-ISA) and individual (FII, FinScope) levels with labeled variables, which can be used to estimate summary statistics for the indicators.
All the instruments include nationally-representative samples. All estimates from the LSMS-ISA are household-level cluster-weighted means, while all estimates from FII and FinScope are calculated as individual-level weighted means. The proportions in the Indicators Spreadsheet are therefore estimates of the true proportion of individuals/households in the national population during the year of the survey. EPAR also created a Tableau visualization of these summary statistics, which can be found here.
We have also prepared a document outlining the construction decisions for each indicator across survey instruments and countries. We attempted to follow the same construction approach across instruments, and note any situations where differences in the instruments made this impossible.
The spreadsheet includes estimates of the following indicators created in our code files:
- Proportion of individuals who have access to a mobile phone
- Proportion of individuals who have official identification
- Proportion of individuals who are female
- Proportion of individuals who use mobile money
- Proportion of individuals who have a bank account
- Proportion of individuals who live in a rural area
- Individual Poverty Status
- Two Lowest PPI Quintiles
- Middle PPI Quintile
- Two Highest PPI Quintiles
Coverage & Prevalence
- Proportion of individuals who have interacted with a SHG
- Proportion of individuals who have used an SHG for financial services
- Proportion of individuals who depend most on SHGs for financial advice
- Proportion of individuals who have received financial advice from a SHG
- Proportion of households that have interacted with a SHG
- Proportion of households in communities with at least one SHG
- Proportion of households in communities with access to multiple farmer cooperative groups
- Proportion of households who have used an SHG for financial services
In addition, we produced estimates for 29 indicators related to characteristics of SHG use including indicators related to frequency of SHG use, characteristics of SHG groups, and individual/household trust of SHGs.
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
In this brief, we report on measures of economic growth, poverty and agricultural activity in Ethiopia. For each category of measure, we first describe different measurement approaches and present available time series data on selected indicators. We then use data from the sources listed below to discuss associations within and between these categories between 1994 and 2017.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
Cash transfer programs are interventions that directly provide cash to target specific populations with the aim of reducing poverty and supporting a variety of development outcomes. Low- and middle-income countries have increasingly adopted cash transfer programs as central elements of their poverty reduction and social protection strategies. Bastagli et al. (2016) report that around 130 low- and middle-income countries have at least one UCT program, and 63 countries have at least one CCT program (up from 27 countries in 2008). Through a comprehensive review of literature, this report primarily considers the evidence of the long-term impacts of cash transfer programs in low- and lower middle-income countries. A review of 54 reviews that aggregate and summarize findings from multiple studies of cash transfer programs reveals largely positive evidence on long-term outcomes related to general health, reproductive health, nutrition, labor markets, poverty, and gender and intra-household dynamics, though findings vary by context and in many cases overall conclusions on the long-term impacts of cash transfers are mixed. In addition, evidence on long-term impacts for many outcome measures is limited, and few studies explicitly aim to measure long-term impacts distinctly from immediate or short-term impacts of cash transfers.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
By examining how farmers respond to changes in crop yield, we provide evidence on how farmers are likely to respond to a yield-enhancing intervention that targets a single staple crop such as maize. Two alternate hypotheses we examine are: as yields increase, do farmers maintain output levels but change the output mix to switch into other crops or activities, or do they hold cultivated area constant to increase their total production quantity and therefore their own consumption or marketing of the crop? This exploratory data analysis using three waves of panel data from Tanzania is part of a long-term project examining the pathways between staple crop yield (a proxy for agricultural productivity) and poverty reduction in Sub-Saharan Africa.
This research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. We summarize the public good characteristics of R&D for agriculture in general and for commodity and subsistence crops in particular, as well as R&D for health in general and for neglected diseases in particular, with a focus on Sub-Saharan Africa and South Asia. Finally, we present rationales for which funders are predicted to fund which R&D types based on these funder and R&D characteristics. We then compile available statistics on funding for agricultural and health R&D from private, public and philanthropic sources, and compare trends in funding from these sources against expectations. We find private agricultural R&D spending focuses on commodity crops (as expected). However contrary to expectations we find public and philanthropic spending also goes largely towards these same crops rather than staples not targeted by private funds. For health R&D private funders similarly concentrate on diseases with higher potential financial returns. However unlike in agricultural R&D, in health R&D we observe some specialization across funders – especially for neglected diseases R&D - consistent with funders’ expected relative advantages.